Nathan Rice

Stock Analyst at Piper Sandler

(3.00)
# 1,359
Out of 5,116 analysts
61
Total ratings
52.63%
Success rate
9.93%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $139.50
Upside: +7.53%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $42.03
Upside: +14.20%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $41.46
Upside: +1.30%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $31.93
Upside: +9.61%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $74.52
Upside: -0.70%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $145.98
Upside: -42.46%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $163.03
Upside: +20.84%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $24.08
Upside: -62.62%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $670.46
Upside: -35.12%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $274.11
Upside: -15.00%
Initiates: Neutral
Price Target: $83
Current: $43.32
Upside: +91.60%
Initiates: Overweight
Price Target: $15
Current: $19.84
Upside: -24.40%